Probuphine is a subdural slow-release form of the opioid drug buprenorphine.
The medication is implanted under the skin, most often in the arm. It releases buprenorphine into your system over a period of six months.
Buprenorphine is a partial opioid agonist, meaning that it works similarly to opioid drugs, but it does not fully activate the opioid receptors in your brain. It does occupy the opioid receptors — the same neural receptors in the brain that are occupied by the major opioid drugs of abuse like heroin, hydrocodone products, and oxycodone products.
When you take buprenorphine, you will not receive the full psychoactive effects (the rush or buzz) of an opioid, but your brain will act as if you have taken those same drugs. If you use buprenorphine in recovery, you will not experience the severe withdrawal symptoms that you normally would in the early stages of opioid detox.
Subutex, Suboxone, Sublocade, and Buprenex are some of the brand names for medications that contain buprenorphine. They are used to manage withdrawal symptoms for people in the early stages of recovery from opioid use disorders.
Medications can be effective in the treatment of opioid dependence due to the very unique effects that opioids have on your brain.
The relapse rate associated with traditional medical detox for opioid use disorders is high. Use of buprenorphine has been demonstrated to improve long-term outcomes for people recovering from opioid use disorders.
An opioid use disorder is a substance use disorder (a form of substance abuse or addiction) that occurs when individuals abuse opioids.
According to a recent review article in Therapeutic Advances in Psychopharmacology, buprenorphine has been very successful in the treatment of opioid withdrawal symptoms, but it has also become a victim of its own success. There are various downsides to using buprenorphine.
The subdural implant addresses all of these issues.
According to the website of the manufacturer of Probuphine, a physician places the implant of the medication under your skin, typically in your arm. The medication is slowly released into your bloodstream, where it travels to your brain.
The medication effectively blocks withdrawal from opioid drugs and also reduces cravings for opioids, although it is more effective at blocking withdrawal symptoms. Other medications like naltrexone (ReVia) may also be required to fully address cravings.
The implant remains in your arm for six months. It must then be removed by a physician. After the six-month period, you could opt to have another implant placed in your arm.
There is no cure for any form of substance use disorder (addiction). Medication-assisted treatments like buprenorphine can assist you in recovery from an opioid use disorder, but the use of medications alone is not sufficient to address your addictive behaviors.
Medications need to be combined with behavioral interventions, like substance use disorder therapy, group participation, family support, and education about addictive behaviors in order for you to have a well-rounded recovery program. No matter how successful you are in your treatment and recovery, you will always be at an increased risk for relapse compared to people who never developed a substance use disorder.
Probuphine was approved by the Food and Drug Administration (FDA) in 2016.
There have been several research studies that contributed to its approval for the treatment of opioid use disorders. There were three main preliminary studies.
Several other subsequent RCTs delivered similar results regarding the effectiveness of Probuphine implants.
Based on the research studies and information provided on the manufacturer’s website, there are obviously several advantages to using Probuphine implants.
You do not have to worry about forgetting to take your medication, like you do with sublingual buprenorphine, pills, or even injections.
The medication cannot be stolen from you, and it cannot be abused by others.
The implant is a more effective way of delivering the medication to your brain.
The medication can also reduce urges to relapse because it is already in your system. You do not face the daily choice of taking your buprenorphine or trying to go back to using your opioid of choice.
There is no risk of accidental use of the drug by small children or pets.
For incarcerated people with opioid use disorders, implants present a great way to treat withdrawal symptoms and continue treatment while they are incarcerated. At the current time, it is unclear if the use of the implants would reduce recidivism rates in incarcerated individuals with opioid use disorders once they are released, but the speculation is that they would.
There is no such thing as a medication that is a panacea or that only produces positive effects. Any intervention induces some risk.
Based on the manufacturer’s website information, there is a risk of infection or nerve damage associated with the procedure of installing and removing the implant. An embolism (a blood clot) could form and be fatal in rare cases.
There has been some concern that physicians and psychiatrists who prescribe other buprenorphine products may not be motivated to learn the surgical procedure. Because of the regulations involved, it is also possible that a surgeon and the prescribing physician may be required to be present when the procedure is performed, leading to insurance concerns about paying for the services of two physicians when only one is really needed. This may lead to the product not being fully available.
There are some concerns that people who use the implant may believe this is a six-month cure and neglect other important aspects of their treatment. The treatment team should emphasize that the medication is not a cure for an opioid use disorder. Therapy and other interventions are still required.
Buprenorphine can interact with other medications. Discuss any medications you have been taking and any allergies you have with your physician prior to using any form of the drug. Certain medical conditions may disqualify you from using the medication.
Probuphine should only be used under the supervision of a physician, and the implant should only be installed by a qualified physician.
According to a 2018 article in American Family Physician, the cost per implant is about $1,294. Four implants are required for the six-month treatment regime, bringing the final cost to about $5,175.
Obviously, if your insurance covers this treatment, your cost could be significantly less. In most cases, insurance companies cover the cost of medically assisted treatments for people in recovery. However, due to the special qualifications needed to install the implant, you should check with the customer service department at your insurance provider to find out if the implant is covered under your policy.
The question of whether the medication is worth the cost and risk is a personal one. Per the research studies, the implants are obviously effective. If you have relapsed previously when trying to recover from an opioid use disorder, this may be an approach that can benefit you.
Again, Probuphine is not a standalone treatment for any opioid use disorder, and it is not a cure for addiction. You will still have to be involved in therapy, support groups, family therapy, and other needed interventions as identified in your treatment plan.
The ultimate decision will be made by you and your treatment team. They will weigh the pros and cons with you, and they’ll help you make the best choice for your particular situation.
(2019) Buprenorphine Subdermal Implant. Medscape. Retrieved July 2019 from https://reference.medscape.com/drug/probuphine-buprenorphine-subdermal-implant-999824
(May 2019) Buprenorphine. Substance Abuse and Mental Health Services Administration. Retrieved July 2019 from https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine
(November 2008) Extended vs short-term buprenorphine–naloxone for treatment of opioid-addicted youth: a randomized trial. Journal of the American Medical Association. Retrieved July 2019 from http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.184.6664&rep=rep1&type=pdf
(January 2018) Opioid Agonists, Partial Agonists, Antagonists: Oh My! Pharmacy Times. Retrieved July 2019 from https://www.pharmacytimes.com/contributor/jeffrey-fudin/2018/01/opioid-agonists-partial-agonists-antagonists-oh-my
(2013) The Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition. American Psychiatric Association. from #
(March 2017) Probuphine® (buprenorphine implant): A promising candidate in opioid dependence. Therapeutic Advances in Psychopharmacology. Retrieved July 2019 from https://journals.sagepub.com/doi/pdf/10.1177/2045125316681984
(2018) What Is Probuphine (buprenorphine)? Titan Pharmaceuticals. Retrieved July 2019 from https://probuphine.com/about-probuphine/
(May 2019) Naltrexone. Substance Abuse and Mental Health Services Administration. Retrieved July 2019 from https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone
(January 2018) Principles of Effective Treatment. National Institute on Drug Abuse. Retrieved July 2019 from https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment
(May 2016) FDA approves first buprenorphine implant for treatment of opioid dependence. Food and Drug Administration. Retrieved July 2019 from https://www.fda.gov/news-events/press-announcements/fda-approves-first-buprenorphine-implant-treatment-opioid-dependence
(February 2010) In‐vitro and in‐vivo characterization of a buprenorphine delivery system. Journal of Pharmacy and Pharmacology. Retrieved July 2019 from https://onlinelibrary.wiley.com/doi/abs/10.1211/jpp.58.3.0002
(July 2009) Open label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug and Alcohol Dependence. Retrieved July 2019 from https://www.sciencedirect.com/science/article/abs/pii/S0376871609000866
(October 2010) Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. Journal of the American Medical Association. Retrieved July 2019 from https://jamanetwork.com/journals/jama/article-abstract/186711
(November 2018) Buprenex (buprenorphine). RxList. Retrieved July 2019 from https://www.rxlist.com/consumer_buprenorphine_buprenex/drugs-condition.htm
(May 2018) Implantable Buprenorphine (Probuphine) for Maintenance Treatment of Opioid Use Disorder. American Family Physician. Retrieved July 2019 from https://www.aafp.org/afp/2018/0515/p668.html
Buprenorphine, Hcl Tablet, Sublingual. WebMD. Retrieved July 2019 from https://www.webmd.com/drugs/2/drug-64748/buprenorphine-sublingual/details
(February 2018) Buprenorphine Sublingual and Buccal (Opioid Dependence). MedlinePlus. Retrieved July 2019 from https://medlineplus.gov/druginfo/meds/a605002.html
(December 2005) Buprenorphine: A relatively new treatment for opioid dependence. Psychiatry. Retrieved July 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994593/
What Exactly Is Buprenorphine? The National Alliance for Advocates for Buprenorphine Treatment. Retrieved July 2019 from https://www.naabt.org/faq_answers.cfm?ID=2
Buprenorphine. Drug Enforcement Administration. Retrieved July 2019 from https://www.deadiversion.usdoj.gov/drug_chem_info/buprenorphine.pdf
(May 2006) Managing Opioid Addiction With Buprenorphine. American Family Physician. Retrieved July 2019 from https://www.aafp.org/afp/2006/0501/p1573.html
(September 2004) Intelligence Bulletin: Buprenorphine: Potential for Abuse. National Drug Intelligence Center. Retrieved July 2019 from https://www.justice.gov/archive/ndic/pubs10/10123/index.htm
(March/April 2019) Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. Journal of Addiction Medicine. Retrieved July 2019 from https://journals.lww.com/journaladdictionmedicine/Abstract/2019/04000/Buprenorphine_Pharmacology_Review__Update_on.4.aspx
(August 2019) It’s the Go-To Drug to Treat Opioid Addiction. Why Won’t More Pharmacies Stock It? NPR. Retrieved August 2019 from https://www.npr.org/sections/health-shots/2019/08/13/741113454/its-the-go-to-drug-for-opioid-addiction-so-why-won-t-more-pharmacists-stock-it